MedTrace Logo

To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers

NCT05351840 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2022-08-12

No results posted yet for this study

Summary

To evaluate and compare the pharmacokinetic interactions and safety of multiple dose of Treatment A and Treatment B alone and in combination

Conditions

  • Healthy

Interventions

DRUG

LivaloV

Treatment A, Tablet, Oral, QD for 7 Days

DRUG

A

Treatment B, Tablet, Oral, QD for 10 Days

DRUG

LivaloVA

Treatment C, Tablet, Oral, QD for 7 Days

Sponsors & Collaborators

Principal Investigators

  • Jang Hee Hong, PI · Clinical Trial Center, Chungnam National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-02
Primary Completion
2020-12-19
Completion
2021-01-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05351840 on ClinicalTrials.gov